The ability of TLR agonists to upregulate Brucella abortus strain RB51 mediated protection in a murine respiratory model

Brucella abortus is amongst the top 5 zoonotic diseases worldwide. The overall goal of this research is to generate a safe and effective vaccine for humans. Brucella abortus strain RB51, approved for use in cattle, provides protection by initiating a strong T-helper 1 (Th1) type response is a candid...

Full description

Bibliographic Details
Main Author: Walker, Michelle Kay
Other Authors: Veterinary Medicine
Format: Others
Published: Virginia Tech 2015
Subjects:
Online Access:http://hdl.handle.net/10919/54564
id ndltd-VTETD-oai-vtechworks.lib.vt.edu-10919-54564
record_format oai_dc
spelling ndltd-VTETD-oai-vtechworks.lib.vt.edu-10919-545642020-09-29T05:41:55Z The ability of TLR agonists to upregulate Brucella abortus strain RB51 mediated protection in a murine respiratory model Walker, Michelle Kay Veterinary Medicine Witonsky, Sharon G. Zimmerman, Kurt L. Sriranganathan, Nammalwar Kanevsky, Isis Brucella abortus innate immunity dendritic cells vaccine strains RB51 toll-like receptors intranasal vaccination Brucella abortus is amongst the top 5 zoonotic diseases worldwide. The overall goal of this research is to generate a safe and effective vaccine for humans. Brucella abortus strain RB51, approved for use in cattle, provides protection by initiating a strong T-helper 1 (Th1) type response is a candidate vaccine. Based on a model for aerosol exposure mice were vaccinated intranasally (IN) with strain RB51 and challenged IN with B. abortus strain 2308, strain RB51 did not protect. Protection against Brucella is mediated through TLRs 2, 4 and 9. The addition of TLR 2 or TLR 4 and a trend with TLR9 agonists with intranasal RB51 vaccination significantly increased bacterial clearance in the lung after strain 2308 challenge. Therefore, we hypothesized that combining TLR agonists 2, 4, and 9 with strain RB51 IN would upregulate protection and clearance in the lung against strain 2308 challenge (IN), by upregulating the DC1 and CD4 Th1 and CD8 immune response. This study showed that protection is not upregulated by combining all TLR agonists. Overall the addition of TLR 2 and 4 vs. TLR 2, 4 and 9 agonists affects the immune response and impacts the level of clearance. Our data support the development of a DC1 Th1 CD8 response, based on serology, and both DC and T-cell activation and function by the group which received the TLR 2 and 4 agonists and to a lesser degree the group receiving TLR 2, 4, and 9 agonists. Additional studies are warranted to further define the differential mechanisms and endpoints of protection. Master of Science 2015-07-18T06:00:20Z 2015-07-18T06:00:20Z 2014-01-23 Thesis vt_gsexam:1814 http://hdl.handle.net/10919/54564 In Copyright http://rightsstatements.org/vocab/InC/1.0/ ETD application/pdf Virginia Tech
collection NDLTD
format Others
sources NDLTD
topic Brucella abortus
innate immunity
dendritic cells
vaccine strains RB51
toll-like receptors
intranasal vaccination
spellingShingle Brucella abortus
innate immunity
dendritic cells
vaccine strains RB51
toll-like receptors
intranasal vaccination
Walker, Michelle Kay
The ability of TLR agonists to upregulate Brucella abortus strain RB51 mediated protection in a murine respiratory model
description Brucella abortus is amongst the top 5 zoonotic diseases worldwide. The overall goal of this research is to generate a safe and effective vaccine for humans. Brucella abortus strain RB51, approved for use in cattle, provides protection by initiating a strong T-helper 1 (Th1) type response is a candidate vaccine. Based on a model for aerosol exposure mice were vaccinated intranasally (IN) with strain RB51 and challenged IN with B. abortus strain 2308, strain RB51 did not protect. Protection against Brucella is mediated through TLRs 2, 4 and 9. The addition of TLR 2 or TLR 4 and a trend with TLR9 agonists with intranasal RB51 vaccination significantly increased bacterial clearance in the lung after strain 2308 challenge. Therefore, we hypothesized that combining TLR agonists 2, 4, and 9 with strain RB51 IN would upregulate protection and clearance in the lung against strain 2308 challenge (IN), by upregulating the DC1 and CD4 Th1 and CD8 immune response. This study showed that protection is not upregulated by combining all TLR agonists. Overall the addition of TLR 2 and 4 vs. TLR 2, 4 and 9 agonists affects the immune response and impacts the level of clearance. Our data support the development of a DC1 Th1 CD8 response, based on serology, and both DC and T-cell activation and function by the group which received the TLR 2 and 4 agonists and to a lesser degree the group receiving TLR 2, 4, and 9 agonists. Additional studies are warranted to further define the differential mechanisms and endpoints of protection. === Master of Science
author2 Veterinary Medicine
author_facet Veterinary Medicine
Walker, Michelle Kay
author Walker, Michelle Kay
author_sort Walker, Michelle Kay
title The ability of TLR agonists to upregulate Brucella abortus strain RB51 mediated protection in a murine respiratory model
title_short The ability of TLR agonists to upregulate Brucella abortus strain RB51 mediated protection in a murine respiratory model
title_full The ability of TLR agonists to upregulate Brucella abortus strain RB51 mediated protection in a murine respiratory model
title_fullStr The ability of TLR agonists to upregulate Brucella abortus strain RB51 mediated protection in a murine respiratory model
title_full_unstemmed The ability of TLR agonists to upregulate Brucella abortus strain RB51 mediated protection in a murine respiratory model
title_sort ability of tlr agonists to upregulate brucella abortus strain rb51 mediated protection in a murine respiratory model
publisher Virginia Tech
publishDate 2015
url http://hdl.handle.net/10919/54564
work_keys_str_mv AT walkermichellekay theabilityoftlragoniststoupregulatebrucellaabortusstrainrb51mediatedprotectioninamurinerespiratorymodel
AT walkermichellekay abilityoftlragoniststoupregulatebrucellaabortusstrainrb51mediatedprotectioninamurinerespiratorymodel
_version_ 1719345340046376960